IOVANCE BIOTHERAPEUTICS, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $1.29 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2016-11-04
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2016-09-30 was -$1.68M, a 270.07% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2016-06-30 was $2.78M.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2016-03-31 was $200.00K, a 19.68% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2015-12-31 was -$1.23M, a 403.22% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2015 was -$32.00K.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2014 was -$608.00K.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2013 was -$98.00K, a 105.23% decline from fiscal 2012.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2012 was $1.88M.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 54 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 57 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 60 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 66 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 69 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 72 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 78 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-09-30 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.09M derived: sum of 2 quarters · filed 2016-11-04 | $1.29M 10-Q · filed 2016-11-04 | $69.00K derived: sum of 4 quarters · filed 2016-11-04 | |||||||||||
| 2016-06-30 | $2.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $2.98M 10-Q · filed 2016-08-09 | $1.75M derived: sum of 3 quarters · filed 2016-08-09 | $2.74M derived: sum of 4 quarters · filed 2016-11-04 | |||||||||||
| 2016-03-31 | $200.00K 10-Q · filed 2016-05-09 | -$1.02M derived: sum of 2 quarters · filed 2016-05-09 | -$36.00K derived: sum of 3 quarters · filed 2016-11-04 | -$81.00K derived: sum of 4 quarters · filed 2016-11-04 | |||||||||||
| 2015-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$236.00K derived: sum of 2 quarters · filed 2016-11-04 | -$281.00K derived: sum of 3 quarters · filed 2016-11-04 | -$32.00K 10-K · filed 2016-03-11 | |||||||||||
| 2015-09-30 | $989.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $944.00K derived: sum of 2 quarters · filed 2016-11-04 | $1.19M 10-Q · filed 2016-11-04 | $1.60M derived: sum of 4 quarters · filed 2016-11-04 | |||||||||||
| 2015-06-30 | -$45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $204.00K 10-Q · filed 2016-08-09 | $204.44K 10-Q · filed 2015-08-10 | $608.00K derived: sum of 3 quarters · filed 2016-08-09 | $709.46K derived: sum of 4 quarters · filed 2016-08-09 | ||||||||||
| 2015-03-31 | $249.00K 10-Q · filed 2016-05-09 | $248.96K 10-Q · filed 2015-05-11 | $653.00K derived: sum of 2 quarters · filed 2016-05-09 | $754.46K derived: sum of 3 quarters · filed 2016-05-09 | $634.39K derived: sum of 4 quarters · filed 2016-05-09 | ||||||||||
| 2014-12-31 | $404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $505.46K derived: sum of 2 quarters · filed 2016-03-11 | $385.39K derived: sum of 3 quarters · filed 2016-03-11 | -$608.00K 10-K · filed 2016-03-11 | -$354.94K 10-K · filed 2015-03-16 | ||||||||||
| 2014-09-30 | $101.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$18.61K derived: sum of 2 quarters · filed 2015-11-06 | -$1.01M 10-Q · filed 2015-11-06 | -$1.01M 10-Q · filed 2014-11-13 | -$1.78M derived: sum of 4 quarters · filed 2016-03-11 | ||||||||||
| 2014-06-30 | -$120.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$1.11M 10-Q · filed 2015-08-10 | -$1.88M derived: sum of 3 quarters · filed 2016-03-11 | -$2.19M derived: sum of 4 quarters · filed 2016-03-11 | |||||||||||
| 2014-03-31 | -$993.39K 10-Q · filed 2015-05-11 | -$1.16M 10-Q · filed 2014-05-14 | -$1.76M derived: sum of 2 quarters · filed 2016-03-11 | -$2.07M derived: sum of 3 quarters · filed 2016-03-11 | -$1.41M derived: sum of 4 quarters · filed 2016-03-11 | $1.13M 10-Q · filed 2014-05-14 | |||||||||
| 2013-12-31 | -$768.59K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$1.07M derived: sum of 2 quarters · filed 2016-03-11 | -$414.45K derived: sum of 3 quarters · filed 2016-03-11 | -$98.00K 10-K · filed 2016-03-11 | $445.74K 10-K · filed 2014-03-28 | $2.47M 10-K · filed 2014-03-28 | |||||||||
| 2013-09-30 | -$305.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $354.15K derived: sum of 2 quarters · filed 2014-11-13 | $670.59K 10-Q · filed 2014-11-13 | $488.09K derived: sum of 4 quarters · filed 2014-11-13 | $5.98M 10-Q · filed 2013-11-14 | ||||||||||
| 2013-06-30 | $659.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $976.32K 10-Q · filed 2014-08-08 | $976.32K 10-Q · filed 2013-10-23 | $793.82K derived: sum of 3 quarters · filed 2014-08-08 | $2.15M derived: sum of 4 quarters · filed 2014-08-08 | $5.84M 10-Q · filed 2013-10-23 | |||||||||
| 2013-03-31 | $316.45K 10-Q · filed 2014-05-14 | $658.06K 10-Q · filed 2013-10-23 | $133.94K derived: sum of 2 quarters · filed 2014-05-14 | $1.49M derived: sum of 3 quarters · filed 2014-05-14 | $1.82M derived: sum of 4 quarters · filed 2014-05-14 | $5.53M 10-Q · filed 2013-10-23 | |||||||||
| 2012-12-31 | -$182.51K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | $1.18M derived: sum of 2 quarters · filed 2014-03-28 | $1.50M derived: sum of 3 quarters · filed 2014-03-28 | $1.88M 10-K · filed 2014-03-28 | |||||||||||
| 2012-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $1.69M derived: sum of 2 quarters · filed 2013-11-14 | $2.06M 10-Q · filed 2013-11-14 | $616.00K 10-Q · filed 2013-01-25 | $616.00K 10-Q · filed 2013-01-25 | ||||||||||
| 2012-06-30 | $327.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-23 | $700.06K 10-Q · filed 2013-10-23 | $616.00K 10-Q/A · filed 2012-09-10 | $616.00K 10-Q/A · filed 2012-09-10 | |||||||||||
| 2012-03-31 | $372.18K 10-Q · filed 2013-10-23 | $866.00K 10-Q · filed 2012-05-15 | $866.00K 10-Q · filed 2012-05-15 | ||||||||||||
| 2011-09-30 | $0.00 10-Q · filed 2013-01-25 | ||||||||||||||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |